Effect of iron-contained phosphate binder on serum FGF23 in hemodialysis patients.

Effect of iron-contained phosphate binder on serum FGF23 in hemodialysis patients. - Effect of iron-contained phosphate binder on serum FGF23 in hemodialysis patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013972

Enrollment

Registered

2014-05-19

Start date

2014-05-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

Converting of phosphate binder for sevelamer-HCl to ferric citrate hydrate in hemodialysis patients.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hemodialysis patients with sevelamer-HCl

Exclusion criteria

Exclusion criteria: excess of iron

Design outcomes

Primary

Measure	Time frame
the change of serum FGF23 concentration	—

Countries

Japan

Contacts

Public ContactAkira Iguchi

Ojiya general hospital internal medicine

igucci4444@yahoo.co.jp0258-83-3600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026